What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to ...
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...
To a passerby, the glass-fronted 10 Prospect building rising above the low-slung restaurant and retail space of Somerville's ...
Iambic Therapeutics is aiming for a $135 million IPO in net proceeds as the AI biotech looks to fund the clinical development ...
A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that ...
Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...
TCGX is expanding its operations to Asia in connection with the fund, opening offices in Shanghai and Hong Kong. Dandan Dong, ...
Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...
Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
MimiVax's cancer vaccine missed the primary endpoint of a phase 2 study in patients with newly diagnosed glioblastoma, although the biotech claimed it can still see a path forward for the candidate | ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results